Oslo, 17.07.2012. HIV- and Oncology Research Expert Professor Gus Dalgleish Joins Clinical Advisory Board Bionor Pharma. Professor Dalgleish joins growing global board to help find a cure or functional cure for HIV Bionor Pharma ASA announced today that the HIV expert from the UK based St. George’s University of London, Professor Angus “Gus” Dalgleish is …
Oslo 07.06.2012 – Vacc-HIV is a combination of Vacc-4x and Vacc-C5. The combined patent is developed for further protection of the two vaccines alone, in addition to protecting the use of these vaccines in combination Bionor Pharma ASA announced today that it has initiated the international patent process for protection of the Company`s peptide vaccine …
Oslo 29.05.2012 – Animal Studies Indicate Similar Generation of Immune Responses as Those in HIV Patients who Naturally Suppress the Infection News Summary Open, clinical study, dose escalating, phase I/II, with Bionor Pharma`s second therapeutic HIV vaccine to begin at Oslo University Hospital. Researchers hope Vacc-C5 will prevent hyperactivation of immune system that leads to …
